Skip to main content

BioAtla, Inc.

BCAB
Exchange
OTC
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001826892

No open-market purchases or sales by BioAtla, Inc. insiders were filed in the last 90 days; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.22M in total; no superinvestor holds it.

Q1 2023 vs. Q4 2022

How the institutions holding BioAtla, Inc. changed between Q4 2022 and Q1 2023.

All holders in Q1 2023All holders in Q4 2022

13F holders of BCAB: Q4 2022 compared with Q1 2023
MeasureQ4 2022Q1 2023Change
Holders9181−10
Shares33.8M32.7M−1.12M (−3.3%)
Value$279.2M$87.6M−$191.6M (−68.6%)

New holders (14)

Institutions that held BioAtla, Inc. at the end of Q1 2023 but not at the end of Q4 2022.

Institutions new to BCAB in Q1 2023
InstitutionSharesValue% of portfolio
Healthcare of Ontario Pension Plan Trust Fund512,300$1.37M0.01%
Wellington Management Group LLP365,228$978.8K0.00%
UBS Oconnor LLC245,025$656.7K0.02%
MYDA Advisors LLC55,000$147.4K0.06%
Connor, Clark & Lunn Investment Management Ltd.48,614$130.3K0.00%
Jump Financial, LLC46,800$125.4K0.01%
Occudo Quantitative Strategies LP21,719$58.2K0.01%
SC&H Financial Advisors, Inc.21,400$57.4K0.02%
Diametric Capital, LP16,298$43.7K0.02%
Algert Global LLC15,560$41.7K0.00%
Bank of Montreal11,077$30.6K0.00%
Virtu Financial LLC10,302$28.0K0.00%
Quantbot Technologies LP4,851$13.0K0.00%
Zurcher Kantonalbank (Zurich Cantonalbank)3,085$8.27K0.00%

Sold out (24)

Institutions that held BioAtla, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.